Journal of International Oncology ›› 2021, Vol. 48 ›› Issue (5): 302-307.doi: 10.3760/cma.j.cn371439-20200819-00058
• Reviews • Previous Articles Next Articles
Long Xin, Wu Han, Peng Jin, Zhou Fuxiang()
Received:
2020-08-19
Revised:
2021-02-21
Online:
2021-05-08
Published:
2021-06-09
Contact:
Zhou Fuxiang
E-mail:happyzhoufx@sina.com
Long Xin, Wu Han, Peng Jin, Zhou Fuxiang. Systemic therapy of advanced biliary tract cancer[J]. Journal of International Oncology, 2021, 48(5): 302-307.
[1] |
Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise[J]. Oncologist, 2016,21(5):594-599. DOI: 10.1634/theonco-logist.2015-0446.
doi: 10.1634/theoncologist.2015-0446 |
[2] |
Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018,15(2):95-111. DOI: 10.1038/nrclinonc.2017.157.
doi: 10.1038/nrclinonc.2017.157 |
[3] | Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling[J]. Am Soc Clin Oncol Educ Book, 2016,35:e194-e203. DOI: 10.1200/EDBK_160831. |
[4] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010,362(14):1273-1281. DOI: 10.1056/NEJMoa0908721.
doi: 10.1056/NEJMoa0908721 |
[5] |
Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent bi-liary tract cancer: the FUGA-BT (JCOG1113) randomized phase Ⅲ clinical trial[J]. Ann Oncol, 2019,30(12):1950-1958. DOI: 10.1093/annonc/mdz402.
doi: 10.1093/annonc/mdz402 |
[6] |
Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2018,4(12):1707-1712. DOI: 10.1001/jamaoncol.2018.3277.
doi: 10.1001/jamaoncol.2018.3277 |
[7] |
Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase Ⅱ trial[J]. Br J Cancer, 2008,98(2):309-315. DOI: 10.1038/sj.bjc.6604178.
doi: 10.1038/sj.bjc.6604178 |
[8] |
Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase Ⅱ trial[J]. J Clin Oncol, 2005,23(10):2332-2338. DOI: 10.1200/JCO.2005.51.008.
doi: 10.1200/JCO.2005.51.008 |
[9] |
Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase Ⅱ trial[J]. Cancer, 2005,103(1):111-118. DOI: 10.1002/cncr.20753.
doi: 10.1002/(ISSN)1097-0142 |
[10] |
Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase Ⅱ clinical trial[J]. JAMA Oncol, 2019,5(6):824-830. DOI: 10.1001/jamaoncol.2019.0270.
doi: 10.1001/jamaoncol.2019.0270 |
[11] |
Yoo C, Han B, Kim HS, et al. Multicenter phase Ⅱ study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer[J]. Cancer Res Treat, 2018,50(4):1324-1330. DOI: 10.4143/crt.2017.526.
doi: 10.4143/crt.2017.526 |
[12] |
Ulusakarya A, Karaboué A, Ciacio O, et al. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer[J]. BMC Cancer, 2020,20(1):515. DOI: 10.1186/s12885-020-07004-y.
doi: 10.1186/s12885-020-07004-y pmid: 32493242 |
[13] |
Lamarca A, Hubner RA, David Ryder W, et al. Second-line che-motherapy in advanced biliary cancer: a systematic review[J]. Ann Oncol, 2014,25(12):2328-2338. DOI: 10.1093/annonc/mdu162.
doi: 10.1093/annonc/mdu162 |
[14] |
Lamarca A, Palmer DH, Wasan HS, et al. A randomised phase Ⅲ, multi-centre, openlabel study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC + mFOLFOX) for patients with locally advanced/metastatic biliary tract cancers (ABC) previously treated with cisplatin/gemcitabine (CisGem) chemotherapy[J]. J Clin Oncol, 2019,37:4003.
doi: 10.1200/JCO.2019.37.15_suppl.4003 |
[15] | 胆道肿瘤专家委员会. CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J]. 临床肿瘤学杂志, 2019,24(9):828-838. DOI: 10.3969/j.issn.1009-0460.2019.09.014. |
[16] |
Zheng Y, Tu X, Zhao P, et al. A randomised phase Ⅱ study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin[J]. Br J Cancer, 2018,119(3):291-295. DOI: 10.1038/s41416-018-0138-2.
doi: 10.1038/s41416-018-0138-2 |
[17] | Bang YJ, Doi T, Braud FD, et al. Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028[J]. Eur J Cancer, 2015, 51: S112. DOI 10.1016/S0959-8049(16)30326-4. |
[18] |
Bang YJ, Ueno M, Malka D, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies[J]. J Clin Oncol, 2019,37(15_suppl):4079. DOI: 10.1200/JCO.2019.37.15_suppl.4079.
doi: 10.1200/JCO.2019.37.15_suppl.4079 |
[19] | Kim RD, Chung V, Alese OB, et al. A phase Ⅱ multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020,6(6):1-8. DOI: 10.1001/jamaoncol.2020.0930. |
[20] |
Lee SH, Lee HS, Lee SH, et al. Efficacy and safety of pembrolizumab for gemcitabine/cisplatin-refractory biliary tract cancer: a multicenter retrospective study[J]. J Clin Med, 2020,9(6):1769. DOI: 10.3390/jcm9061769.
doi: 10.3390/jcm9061769 |
[21] |
Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase Ⅰ study[J]. Lancet Gastroenterol Hepatol, 2019,4(8):611-621. DOI: 10.1016/S2468-1253(19)30086-X.
doi: 10.1016/S2468-1253(19)30086-X |
[22] | Oh DY, Lee KH, Lee DW, et al. Phase Ⅱ study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC)[J]. J Clin Oncol, 2020, 38(15_suppl: abstr4520. DOI: 10.1200/JCO.2020.38.15_suppl.4520. |
[23] | Sahai V, Griffith KA, Beg MS, et al. A multicenter randomized phase Ⅱ study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01)[J]. J Clin Oncol, 2020, 38(15_suppl): abstr4582. DOI: 10.1200/JCO.2020.38.15_suppl.4582. |
[24] | Klein O, Kee D, Nagrial A, et al. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers[[J]. J Clin Oncol, 2020, 38(15_suppl): abstr4588. DOI: 10.1200/JCO.2020.38.15_suppl.4588. |
[25] |
Javle M, Lowery M, Shroff RT, et al. Phase Ⅱ study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma[J]. J Clin Oncol, 2018,36(3):276-282. DOI: 10.1200/JCO.2017.75.5009.
doi: 10.1200/JCO.2017.75.5009 |
[26] | Meric-Bernstam F, Arkenau H, Tran B, et al. O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors[J]. Ann Oncol, 2018,29(suppl_5):v100-v110. DOI: 10.1093/annonc/mdy149. |
[27] |
Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase Ⅱ study[J]. Lancet Oncol, 2020,21(5):671-684. DOI: 10.1016/S1470-2045(20)30109-1.
doi: 10.1016/S1470-2045(20)30109-1 |
[28] |
Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review[J]. J Gastrointest Oncol, 2019,10(4):751-765. DOI: 10.21037/jgo.2019.03.10.
doi: 10.21037/jgo.2019.03.10 pmid: 31392056 |
[29] |
Lowery MA, Burris HA 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase Ⅰ study[J]. Lancet Gastroenterol Hepatol, 2019,4(9):711-720. DOI: 10.1016/S2468-1253(19)30189-X.
doi: 10.1016/S2468-1253(19)30189-X |
[30] |
Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase Ⅲ study[J]. Lancet Oncol, 2020,21(6):796-807. DOI: 10.1016/S1470-2045(20)30157-1.
doi: 10.1016/S1470-2045(20)30157-1 |
[31] |
Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?[J]. Cancer Metastasis Rev, 2017,36(1):141-157. DOI: 10.1007/s10555-016-9645-x.
doi: 10.1007/s10555-016-9645-x |
[32] |
Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer[J]. J Hematol Oncol, 2015,8:58. DOI: 10.1186/s13045-015-0155-z.
doi: 10.1186/s13045-015-0155-z |
[33] | Suder A, Ang JE, Kyle F, et al. A phase Ⅰ study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours[J]. Eur J Cancer, 2015,1(16):2275-2284. DOI: 10.1016/j.ejca.2015.07.041. |
[34] | Tan AC, Oh DY, Chao Y, et al. Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: a pooled analysis from three phase Ⅰ studies[J]. Proc Am Soc Clin Oncol, 2019,37:331. |
[35] |
Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase Ⅱ trial[J]. Lancet Oncol, 2015,16(8):967-978. DOI: 0.1016/S1470-2045(15)00139-4.
doi: 10.1016/S1470-2045(15)00139-4 |
[36] |
Iyer RV, Pokuri VK, Groman A, et al. A multicenter phase Ⅱ study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer[J]. Am J Clin Oncol, 2018,41(7):649-655. DOI: 10.1097/COC.000000000000-0347.
doi: 10.1097/COC.0000000000000347 |
[37] |
Sun W, Patel A, Normolle D, et al. A phase Ⅱ trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma[J]. Cancer, 2019,125(6):902-909. DOI: 10.1002/cncr.31872.
doi: 10.1002/cncr.31872 |
[1] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[2] | Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[3] | Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[4] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[5] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[6] | Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311. |
[7] | Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216. |
[8] | Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[9] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[10] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[11] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[12] | Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113. |
[13] | Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[14] | Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552. |
[15] | Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||